Kevin Conroy, Chairman and CEO at Exact Sciences, shared a post on LinkedIn:
“2025 was a meaningful year for Exact Sciences and for the patients we serve.
We tested over 5.5 million people last year. That is 5.5 million people and families touched by our tests.
In Q4, we generated $878 million in revenue, up 23% from last year. During the quarter, we shared results from the NSABP B-59 substudy and pivotal clinical validation results from the ALTUS study. These data strengthen the science behind our tests and give doctors clearer information to guide care.
Thank you to our team for your focus and accountability. You are helping us detect cancer earlier and move us closer to our goal of reducing global cancer mortality.
Read more in our full Q4 press release here.”
Other articles featuring Kevin Conroy on OncoDaily.